Touchless Care Zinc Oxide Protectant


Crawford Healthcare, Inc.
Human Otc Drug
NDC 69502-004
Touchless Care Zinc Oxide Protectant is a human otc drug labeled by 'Crawford Healthcare, Inc.'. National Drug Code (NDC) number for Touchless Care Zinc Oxide Protectant is 69502-004. This drug is available in dosage form of Spray. The names of the active, medicinal ingredients in Touchless Care Zinc Oxide Protectant drug includes Dimethicone - 20 g/100g Zinc Oxide - 25 g/100g . The currest status of Touchless Care Zinc Oxide Protectant drug is Active.

Drug Information:

Drug NDC: 69502-004
The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Proprietary Name: Touchless Care Zinc Oxide Protectant
Also known as the trade name. It is the name of the product chosen by the labeler.
Product Type: Human Otc Drug
Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing.
Non Proprietary Name: Touchless Care Zinc Oxide Protectant
Also known as the generic name, this is usually the active ingredient(s) of the product.
Labeler Name: Crawford Healthcare, Inc.
Name of Company corresponding to the labeler code segment of the ProductNDC.
Dosage Form: Spray
The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Status: Active
FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved.
Substance Name:DIMETHICONE - 20 g/100g
ZINC OXIDE - 25 g/100g
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
Route Details:TOPICAL
The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Marketing Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Marketing Category: OTC MONOGRAPH FINAL
Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Marketing Start Date: 04 Dec, 2015
This is the date that the labeler indicates was the start of its marketing of the drug product.
Marketing End Date: 11 Jun, 2026
This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Application Number: part347
This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
Listing Expiration Date: 31 Dec, 2023
This is the date when the listing record will expire if not updated or certified by the firm.

OpenFDA Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Manufacturer Name:Crawford Healthcare, Inc.
Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC.
RxCUI:968817
The RxNorm Concept Unique Identifier. RxCUI is a unique number that describes a semantic concept about the drug product, including its ingredients, strength, and dose forms.
Original Packager:Yes
Whether or not the drug has been repackaged for distribution.
UPC:5060077231825
5060077231849
UPC stands for Universal Product Code.
NUI:N0000010282
Unique identifier applied to a drug concept within the National Drug File Reference Terminology (NDF-RT).
UNII:92RU3N3Y1O
SOI2LOH54Z
Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information.
Pharmacologic Class PE:Skin Barrier Activity [PE]
Physiologic effect or pharmacodynamic effect—tissue, organ, or organ system level functional activity—of the drug’s established pharmacologic class. Takes the form of the effect, followed by `[PE]` (such as `Increased Diuresis [PE]` or `Decreased Cytokine Activity [PE]`.
Pharmacologic Class:Skin Barrier Activity [PE]
These are the reported pharmacological class categories corresponding to the SubstanceNames listed above.

Packaging Information:

Package NDCDescriptionMarketing Start DateMarketing End DateSample Available
69502-004-28128 g in 1 BOTTLE, SPRAY (69502-004-28)04 Dec, 2015N/ANo
69502-004-5757 g in 1 BOTTLE, SPRAY (69502-004-57)04 Dec, 2015N/ANo
Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together.

Purpose:

Purpose skin protectant skin protectant

Product Elements:

Touchless care zinc oxide protectant touchless care zinc oxide protectant dimethicone dimethicone cyclomethicone hexamethyldisiloxane lanolin mineral oil microcrystalline wax petrolatum vitamin a palmitate zinc oxide zinc oxide cholecalciferol .alpha.-tocopherol, dl- corn oil

Indications and Usage:

Uses helps treat and prevent diaper rash associated with incontinence associated dermatitis protects minor skin irritation due to excess moisture, urine or stool helps seal out wetness

Warnings:

Warnings do not use on deep puncture wounds, serious burns, or animal bites. for external use only. when using this product do not get into eyes. if contact occurs, rinse eyes thoroughly with water.

Dosage and Administration:

Directions cleanse skin area and allow to dry. shake bottle well before use. spray 4-6 inches from skin. no rub-in is required. apply liberally as often as necessary.

Stop Use:

Stop use and ask a doctor if condition worsens or symptoms last more than 7 days or clear up and occur again within a few days.

Package Label Principal Display Panel:

Package label touchless care zinc oxide protectant spray soothes & protects irritated, denuded skin 25% zinc oxide no-rub application chg compatible crawford healthcare net wt. 4.5oz (128g) 128glabel

Package label zincoxide57g


Comments/ Reviews:

* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.